Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies (original) (raw)
Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency
Thomas Ciulla
Ophthalmic Surgery, Lasers and Imaging Retina, 2017
View PDFchevron_right
Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review
Meri Vukicevic
Psychology, health & medicine, 2015
View PDFchevron_right
Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Popula-Tion-Based Cohort Study
Nina Hautala
View PDFchevron_right
Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol
Hema Ramkumar
Ophthalmology, 2018
View PDFchevron_right
Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1
erdem eriş
Turkish Journal of Ophthalmology
View PDFchevron_right
Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration
Letícia Barroso
Arquivos Brasileiros de Oftalmologia
View PDFchevron_right
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
Bora Eldem
BMC Ophthalmology, 2020
View PDFchevron_right
Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration
Karen Wai
American Journal of Ophthalmic Clinical Trials, 2018
View PDFchevron_right
Defining response to anti-VEGF therapies in neovascular AMD
Sajjad Mahmood
Eye (London, England), 2015
View PDFchevron_right
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents
Vuong pham nguyen
Ophthalmology, 2018
View PDFchevron_right
Failure to Complete Induction in Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Joel Hanhart
International journal of ophthalmology and clinical research, 2018
View PDFchevron_right
Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration
Devinder Chauhan
American Journal of Ophthalmology, 2012
View PDFchevron_right
SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration
Stephan Winnik
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2017
View PDFchevron_right
Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review
Manas Biswal
International journal of ophthalmology, 2016
View PDFchevron_right
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
George Lambrou
Journal of ophthalmology, 2016
View PDFchevron_right
Insights From Survival Analyses During 12 Years of Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
Konstantinos Balaskas
JAMA Ophthalmology
View PDFchevron_right
Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
Polona Mekjavic
Frontiers in Medicine, 2018
View PDFchevron_right
Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
Yasuo Kurimoto
Clinical ophthalmology (Auckland, N.Z.), 2017
View PDFchevron_right
Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis
Corinne Dot
Journal of Clinical Medicine, 2022
View PDFchevron_right
Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration
Ágnes Borbándy
BMC Ophthalmology
View PDFchevron_right
Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration
susan vitale
Ophthalmology Retina, 2019
View PDFchevron_right
Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti–Vascular Endothelial Growth Factor
Jonathan Sears
Ophthalmology Retina, 2018
View PDFchevron_right
When Should Anti-Vascular Endothelial Growth Factor Treatment Be Stopped in Age-Related Macular Degeneration?
Salomon Velasco Cohen
American Journal of Ophthalmology, 2010
View PDFchevron_right
Treatment Paradigms in Neovascular AMD
rishi singh
Current Ophthalmology Reports, 2013
View PDFchevron_right
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Jordi Monés, Anat Loewenstein
The British journal of ophthalmology, 2014
View PDFchevron_right
Long-lasting effects of anti-VEGF/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review
Kent Small
Clinical Ophthalmology, 2014
View PDFchevron_right
The effect of sample medication use on subsequent anti-VEGF agent selection for neovascular age-related macular degeneration
Karen Wai
2021
View PDFchevron_right
Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy:post hocanalysis of the VIEW studies
Alan Cruess
Acta Ophthalmologica, 2018
View PDFchevron_right
Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
Timothy Murray
Clinical Ophthalmology, 2010
View PDFchevron_right
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
Bora Eldem
British Journal of Ophthalmology, 2020
View PDFchevron_right
The Impact of Anti–Vascular Endothelial Growth Factor Treatment on Quality of Life in Neovascular Age-related Macular Degeneration
Jill Keeffe, Robyn Guymer
Ophthalmology, 2014
View PDFchevron_right
Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months
Vuong Nguyen
Ophthalmology Retina, 2019
View PDFchevron_right